Patient Selection and Referral Eligibility for CAR-T Therapy

January 3, 2025

By Sagar Lonial, MD, FACP
Ajay K. Nooka, MD

Opinion

Video

Panelists discuss the key factors that influence their institution's decision to utilize CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma and explain the next steps they would take if choosing CAR-T, including the rationale behind their decisions.

EP: 1.Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 2.Patient Selection and Referral Eligibility for CAR-T Therapy

EP: 3.Understanding the CAR-T Treatment Process

EP: 4.CAR-T Therapy: Approach to Bridging

EP: 5.Care Coordination and Transition Strategies for CAR-T Therapy

EP: 6.CAR-T Therapy in Early Lines of R/R MM: Clinical Scenario Discussion and Key Takeaways

EP: 7.Key Takeaways in CAR-T Therapy for Multiple Myeloma

Video content above is prompted by the following:

What are the key factors that influence your institution's decision to utilize CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma?
If you choose to utilize CAR-T in earlier lines of therapy, what might you do next and why?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!